Inclusion Criteria:

- Signed, written, informed consent must be obtained from the patient or their legal
representative before any study-specific procedures are performed

- Confirmed diagnosis of adenocarcinoma of the colon or rectum not amenable to curative
surgery

- One or more prior systemic therapy regimens for metastatic cancer which must have
included a fluoropyrimidine (5-FU by infusion or capecitabine), oxaliplatin or
irinotecan with or without bevacizumab

Exclusion Criteria:

- Clinically significant obstructive symptoms, intestinal bleeding, or chronic or
recent acute gastrointestinal disorder with diarrhea as a major symptom

- History of unstable or deteriorating cardiovascular or cerebrovascular disease within
3 months before the first dose of protocol therapy

- Clinical evidence of brain metastases or central nervous system disease

- Pregnant or lactating women

- Serious medical or psychiatric illness

- Malignancy other than colorectal carcinoma within the past 2 years, except curatively
treated, superficial skin cancer or carcinoma in situ of the cervix

- Patients who have been on any experimental study or anti-tumor therapy, received
radiotherapy, or had prior surgery (except venous access device placement) within 28
days before the first dose of protocol therapy